February 21, 2022, Shenzhen stock exchange sent a letter of concern to Honz Pharmaceutical Co.Ltd(300086) (SZ 300086, closing price: 8.52 yuan): in response to “the announcement on signing the research cooperation agreement on sulamin sodium for injection disclosed by your company on February 14, your company signed the research cooperation agreement on horizontal scientific research projects with Guangdong Institute of public health” “, your company entrusted Guangdong Public Health Research Institute to study the inhibitory effect and minimum effective concentration of sulamin sodium on different sars-cov-2 virus variants. The announcement shows that considering that sulamin sodium for injection can inhibit RdRp enzyme and purinergic receptor at the same time, and RdRp enzyme is relatively conservative for virus mutation; according to the current Research on sulamin sodium abroad Sodium Ming is used for covid-19 sequelae and other related reports. Your company has decided to continue its research on anti-covid-19. In addition, your company recently said in an interactive and easy reply to investors about whether sulamin sodium for injection belongs to one of the specific drugs for the treatment of covid-19 original and variant strains, that sulamin sodium for injection may be a potential drug for the treatment of covid-19 original and variant strains. ” And so on, Proposed by Shenzhen stock exchange include “Please list the indications, research and development stage and listing process of sulamin sodium for injection, which is under research by your company, and explain the specific basis for your company to judge that sulamin sodium for injection may be a potential drug for the treatment of covid-19 original and variant strains, the objectivity and authority of the relevant basis, whether the relevant basis has an authoritative theoretical basis, and whether the information disclosure is true Be truthful, accurate and complete, and fully prompt relevant risks. ” And other requirements.
From January to June 2021, Honz Pharmaceutical Co.Ltd(300086) business revenue composition: the pharmaceutical industry accounted for 55.69%, medical services accounted for 32.33%, and baby and child health care products accounted for 11.98%.
The chairman of Honz Pharmaceutical Co.Ltd(300086) is Hong Jiangyou, male, 58, with a bachelor’s degree.
